The activist SC 13D/A filed one day prior, combined with this board appointment and the ongoing recapitalization, suggests the activist may be influencing board composition. Monitor for the fifth director announcement and any further 13D amendments or proxy materials.
Price Chart
Executive Summary
Celularity appointed Naveen Jain (founder/CEO of Viome Life Sciences) to its Board, effective after a Rule 14f-1 process, pursuant to board designation rights from the September 2026 financing. Director Diane Parks resigned effective the same time, with no disagreement stated. The appointment follows a SC 13D/A filed one day prior by the Philip & Daniele Barach Family Trust, indicating activist presence within 60 days of a board change.
Key Facts
- Naveen Jain appointed to Board effective after Rule 14f-1 waiting period; designated per board rights from September 2026 financing.
- Diane Parks resigned effective at the same time; no disagreement with company stated.
- Board now consists of Robert J. Hariri, Peter H. Diamandis, Philip A. Barach, and Naveen Jain; a fifth director expected shortly.
- SC 13D/A filed Sept. 28, 2026 by Philip & Daniele Barach Family Trust — activist stake within 60 days of board change.
- No financial figures, revenue, EPS, or guidance disclosed in the filing.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Activist may push for further board changes, strategic alternatives, or capital structure actions.
- No financial data provided — uncertainty around the company's operational and cash position persists.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044917 |
| Exhibit: ex99-1.htm | 0001493152-26-044917 |
| Document: 0001493152-26-044917-index-headers.html | 0001493152-26-044917 |
| Document: 0001493152-26-044917-index.html | 0001493152-26-044917 |
| Document: 0001493152-26-044917.txt | 0001493152-26-044917 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.7500 (+40.48%) |
Sep 30, 2026 26d ago | Press Release | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 29, 2026 27d ago | 8-K | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 28, 2026 28d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 28, 2026 28d ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.7500 (−43.18%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (−46.43%) |
Aug 25, 2026 8w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.7500 (+14.81%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.7500 (−9.23%) |
Jun 30, 2026 16w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.7500 (−25.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers